Cardiac resynchronization therapy: An economic perspective;Terapia de resincronización cardíaca: El punto de vista económico

Revista Espanola de Cardiologia Suplementos

Volumn 5, Issue B, 2005, Pages

  Macías Gallego, Alfonso ^a   Ruiz Granell, Ricardo ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Cardiac resynchronization therapy; Cost effectiveness; Heart failure

Indexed keywords

CARDIAC RESYNCHRONIZATION THERAPY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE CONDUCTION DISTURBANCE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MORTALITY; PUBLIC HEALTH PROBLEM; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW;

EID: 33847685705     PISSN: 11313587     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Davis RC, Hobbs FD, Lip GY. ABC of heart failure, history and epidemiology. BMJ. 2000;320:39-42.
2. Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001;344:873-80.
3. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al. Cardiac resynchronization therapy in chronic heart failure. N Engl J Med. 2002;346:1845-53.
4. Auricchio A, Stellbrink C, Sack S. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol. 2002;39:2026-33.
5. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-50.
6. Cowie MR, Mosterd A, Wood DA. The epidemiology of heart failure. Eur Heart J. 1997;18:208-25.
7. Ho KL, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: The Framingham study. J Am Coll Cardiol. 1993;22 Suppl A:6-13.
8. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, et al. Congestive heart failure in the community. Arch Intern Med. 1999;159:29-34.
9. Levy D, Kenchaian S, Larson MG, Benjamin EJ, Kupka MJ, Ho KL, et al. Long term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397-402.
10. Rodríguez-Artalejo F, Guallar-Castillón P, Banegas JR, Rey J. Variación geográfica en las hospitalizaciones y en la mortalidad por insuficiencia cardíaca congestiva en España, 1980-1993. Rev Esp Cardiol. 2000;53:776-82.
11. Pernenkil R, Vinson JM, Shah AS, Beckham V, Wittenberg C, Rich MW. Course and prognosis in patients with congestive heart failure and normal versus abnormal left ventricular ejection fraction. Am J Cardiol. 1997;79:216-9.
12. Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. Eur J Heart Fail. 2001;3:283-91.
13. American Heart Association Heart and Stroke. Statistical Update 2001. Disponible en: www.americanheart.org.
14. O'Conell JB. The costs of management of heart failure. Clin Cardiol. 2000;23:III6.
15. Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine: part I. Circulation. 2002;106:516-20.
16. Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine: part II. Circulation. 2002;106:626-30.
17. Braunschweig F, Linde C, Gadler F, Ryder L. Reduction of hospital days by biventricular pacing. Eur J Heart Fail. 2000;2:399-406.
18. Dixon LJ, Thompson G, Harbinson M. Cardiac resynchronization therapy, a cost effective treatment for cardiac failure. Eur Heart J. 2002;23 Suppl:3.
19. Curnis A, Caprari F, Macioli G, Bontempi L, Scivales A, Bianchetti F, et al. Economic evaluation of cardiac resynchronization in patients with moderate to severe heart failure. Results of the BRESCIA study. PharmacoEconomics. 2003;5:11-22.
20. Martínez-Ferrer J, Alonso A, Bello C, Rekondo J, Gil P, Sanz M. Evaluación económica de la estimulación biventricular como tratamiento de los pacientes con insuficiencia cardíaca refractaria. Rev Esp Cardiol. 2003;56 Suppl 2:52.
21. Escobar C, Hernández-Madrid A, Blanco B, Escudero J, Marín I, Rondón J, et al. Resincronización cardíaca. Impacto socioeconómico sanitario. Relación coste-beneficio. Rev Esp Cardiol. 2004;57 Suppl 2:192.
22. Nichol G, Kaul P, Huszti E, Bridges JF. Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure. Ann Intern Med. 2004;141:1-9.
23. Auricchio A, Abraham WT. Tratamiento de resincronización cardíaca: estado actual; coste frente a beneficio. Circulation. 2004;109:300-7.
24. Sanders GD, Hlatky MA, Every NR, McDonald KM, Heidenreich PA, Parsons LS, et al. Potencial cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Ann Intern Med. 2001;135:870-83.
25. Lynd LD, O'Brien BJ. Cost-effectiveness of the implantable cardioverter defibrillator: a review of current evidence. J Cardiovasc Electrophysiol. 2003;14:S99-103.
26. Shelton RJ, Velavan P, Nikitin NP, Coletta AP, Clark AL, Rigby AS. Clinical trials update from the American Heart Association meeting: SCD-HeFT cost-effectiveness study. Eur J Heart Fail. 2005;7:127-35.